Easy Access to E-cigarettes for Children in Melbourne, Australia

Regulations by 2FIRSTS.ai
Dec.01.2023
Easy Access to E-cigarettes for Children in Melbourne, Australia
A new study reveals that children in western Melbourne can easily purchase e-cigarettes illegally, raising concerns about underage access.

According to a report by the Australian Broadcasting Corporation (ABC) on November 30, a new study has found that children in the western suburbs of Melbourne, Australia, can easily purchase e-cigarettes illegally.

Easy Access to E-cigarettes for Children in Melbourne, Australia
Type analysis | Image source: ABC

 

A report by the Western Public Health Unit (WPHU) has revealed that the majority of e-cigarette shops are located within a distance of less than 750 meters from schools. Third-party retailers, including both cigarette and e-cigarette stores, account for one-third of all e-cigarette sales outlets, while the rest are comprised of milk bars, grocery stores, convenience stores, cafes, and non-food retailers.

 

WPHU has discovered 59 stores in Brimbank selling e-cigarettes. The average price of e-cigarettes is $25, with prices ranging from $10 to $45.

 

The next phase of the Australian government's crackdown on e-cigarettes is set to begin on January 1st, when the ban on importing disposable e-cigarettes will come into effect. Dr. Romanes, Director of the WPHU, expressed his hope that this will be a turning point.

 

He stated, "At some point next year, there will be a comprehensive ban on the commercial sale of non-prescription e-cigarettes, marking a highly significant moment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Thai police seize over 50,000 illegal e-cigarettes worth more than 10 million baht, main suspect arrested in Bangkok
Thai police seize over 50,000 illegal e-cigarettes worth more than 10 million baht, main suspect arrested in Bangkok
Thai police cracked an illegal e-cigarette smuggling case, seized 50,000 items worth more than 10 million baht (over 310,000 US dollars), arrested several suspects, and cracked down on a cross-border smuggling network.
Sep.23 by 2FIRSTS.ai
InterTabac 2025 Insights | Caffeine and nicotine-free pouches hit the stage as white-label manufacturing and big players enter, heating up competition
InterTabac 2025 Insights | Caffeine and nicotine-free pouches hit the stage as white-label manufacturing and big players enter, heating up competition
2Firsts discovers at the 2025 InterTabac Exhibition in Dortmund, Germany that nicotine pouches are a top category.
Sep.24 by 2FIRSTS.ai
2Firsts Research: VUSE Ultra Promotion in Germany, Free E-Cigarette Kit Worth €24 with Registration
2Firsts Research: VUSE Ultra Promotion in Germany, Free E-Cigarette Kit Worth €24 with Registration
2Firsts discovered during its research in Cologne, Germany, that BAT’s VUSE Ultra is running a promotional campaign. Consumers who register on the VUSE website and enter a dealer code can receive a free e-cigarette kit (including device and pods) worth €24.
Sep.23 by 2FIRSTS.ai
Russia Plans to Allow Regional Vape Sales Bans from September 2026
Russia Plans to Allow Regional Vape Sales Bans from September 2026
Russia’s Ministry of Finance (Минфин) has drafted amendments to an existing licensing bill that would grant regional authorities the power to ban retail sales of vapes and nicotine liquids from September 1, 2026, to September 1, 2031, RBC reported. Stores violating the ban would lose their tobacco retail licenses.
Nov.19 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai